CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2020—Flagship Biosciences launched a clinical diagnostics immuno-oncology service, TissueInsight, which provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment, including information on tumor infiltrating lymphocytes and macrophages.
“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” Trevor Johnson, Flagship CEO, said in a statement. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time, or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”
Pages: 1 2